• Highly precise and accurate SARS-CoV-2 Tests

    for screening patients whose immune system has reacted to SARS-CoV-2 virus.

  • Developed and Manufactured in Spain

    Patented under CSIC Licence

  • Coming soon: SARS-CoV-2 Multiantigen IgG + IgA Assay

    Cytometric Bead Array – Multiplexed Bead-Based Immunoassay

  • High-sensitive and precise Covid-19 test

    For the precise detection of SARS-CoV-2 antibody response and immunity after vaccination. 

    Contact us for further information:

    Innovating to deliver
    high-quality reliable testing technology.

    IMMUNOSTEP mission is to develop and market innovative products that improve diagnostic and clinical research performance and we will continue to keep working every day to deliver high-quality technology in order to fight against the global health emergency by assuring reliable results.

    We work under an extensive program of development  and innovation, through technology licensing, collaborations and internal promotion.


    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus that belongs to the family of coronaviruses, of the genus Betacoronavirus, which emerged in China in the city of Wuhan, Hubei province in December 2019 and was It has spread throughout the world until being declared by WHO as a pandemic in March 2020.

    In response to the Covid-19 pandemic, CSIC research groups have worked in collaboration with Immunostep to develop these serological tests capable of monitoring immunity and vaccunation responses with an estimated accuracy of 98%.


    Our Serological Tests in collaboration with  Spanish Research Council 

    A new serological test for Covid-19 antibodies with a reliability close to 100% has been recently launched to the market, developed by researchers from the Spanish Council for Scientific Research (CSIC), in collaboration with the Madrid Hospitals of La Princesa and La Paz, and produced by Immunostep. The test is based on a protein of the virus that had not been used in diagnosis before, this protein can act as an antigen to reveal the immune response against SARS-CoV-2 with a high proven accuracy.

    Research and Development

    Our goal is to improve serology testing performance by innovating and adapting new technology to collaborate building meaningful clinical investigation. 

    We strongly believe validity and realiability of assessment methods must be the most important characteristics of a well- designed assessment procedure, and so we build our workflows in order to achieve the highest quality in all our products and devices.


    Detecting SARS-CoV-2 immune response with an stimated accuracy of nearly 100%.


    High sensitivity and specifity targeting a new exclusive non-structural protein: Cysteine-like Protease (Mpro).


    Very early antibody detection from the symptoms onset identifying IgG and IgA immunoglobulins.

    N protein


    Spike Protein (S Protein)

    M Protein

    • N protein

    • RNA

    • Spike Protein (S Protein)

    • M Protein

    Why Target Mpro Protein?

    The vast majority of serological tests for specific antibodies to SARS-CoV-2 are based on serum detection of antibodies to either the S protein or the N protein.  In this sense, in an attempt to increase the diagnostic possibilities of COVID-19 patients, this assay is based on the detection of specific antibodies against one of the 16 non-structural proteins, specifically against the main viral protease (Mpro or 3CLpro), which plays a critical role in viral replication.

    Vital Role In Viral Replication

    The Mpro protease plays a vital role in processing the polyproteins that are translated from the viral RNA. Although this protein is not exposed in the viral particle, Mpro is elicited after viral infection. Like other b-coronaviruses, SARS-CoV-2 is a positive-sense RNA virus that expresses multiple proteins as a single polypeptide chain, and Mpro cleaves the polyprotein to release mature proteins for the virus. Inhibitors that can block viral replication are promising potential drug candidates that could be used to treat patients suffering from the COVID-19 coronavirus infection.

    CE/IVD kits are only suitable for clinical use in European Union and countries with EU conformity recognition agreements. Manufactured in Spain by Immunostep under CSIC Patent Licence.